1.     Rao S, Lungu C, Crespo R, Steijaert TH, Gorska A, Palstra RJ, et al. Selective cell death in HIV-1-infected cells by DDX3 inhibitors leads to depletion of the inducible reservoir. Nat Commun. 2021;12(1):2475.
2.     De Crignis E, Hossain T, Romal S, Carofiglio F, Moulos P, Khalid MM, et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife. 2021;10
3.     Stoszko M, Al-Hatmi AMS, Skriba A, Roling M, Ne E, Crespo R, et al. Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency. Sci Adv. 2020;6(33):eaba6617.
4.     Lungu C, Procopio FA, Overmars RJ, Beerkens RJJ, Voermans JJC, Rao S, et al. Inter-Laboratory Reproducibility of Inducible HIV-1 Reservoir Quantification by TILDA. Viruses. 2020;12(9).
5.     Crespo R, Rokx C, Mahmoudi T. Towards the next step: LoViRet patients for HIV-1 cure studies. EBioMedicine. 2020;58:102889.
6.     Bertoldi A, D'Urbano V, Bon I, Verbon A, Rokx C, Boucher C, et al. Development of C-TILDA: A modified TILDA method for reservoir quantification in long term treated patients infected with subtype C HIV-1. J Virol Methods. 2020;276:113778.
7.     Zhao M, De Crignis E, Rokx C, Verbon A, van Gelder T, Mahmoudi T, et al. T cell toxicity of HIV latency reversing agents. Pharmacol Res. 2019;139:524-34.
8.     Stoszko M, Ne E, Abner E, Mahmoudi T. A broad drug arsenal to attack a strenuous latent HIV reservoir. Curr Opin Virol. 2019;38:37-53.
9.     Palstra RJ, de Crignis E, Roling MD, van Staveren T, Kan TW, van Ijcken W, et al. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1. Sci Adv. 2018;4(2):e1701729.
10. Ne E, Palstra RJ, Mahmoudi T. Transcription: Insights From the HIV-1 Promoter. Int Rev Cell Mol Biol. 2018;335:191-243.
11. Marian CA, Stoszko M, Wang L, Leighty MW, de Crignis E, Maschinot CA, et al. Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal. Cell Chem Biol. 2018;25(12):1443-55 e14.
12. Abner E, Stoszko M, Zeng L, Chen HC, Izquierdo-Bouldstridge A, Konuma T, et al. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. J Virol. 2018;92(10).
13. De Crignis E, Mahmoudi T. The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency. Int Rev Cell Mol Biol. 2017;328:197-252.
14. Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, et al. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal. EBioMedicine. 2016;3:108-21.
15. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. Correction: Repressive LTR Nucleosome Positioning by the BAF Complex Is Required for HIV Latency. PLoS Biol. 2015;13(11):e1002302.
16. De Crignis E, Mahmoudi T. HIV eradication: combinatorial approaches to activate latent viruses. Viruses. 2014;6(11):4581-608.
17. Mahmoudi T. The BAF complex and HIV latency. Transcription. 2012;3(4):171-6.
18. Rafati H, Parra M, Hakre S, Moshkin Y, Verdin E, Mahmoudi T. Repressive LTR nucleosome positioning by the BAF complex is required for HIV latency. PLoS Biol. 2011;9(11):e1001206.